Wednesday’s Market Insights: Tesla Motors Inc (TSLA), OvaScience Inc (OVAS), Petroleo Brasileiro SA – Petrobras (ADR) (PBR) Novavax, Inc. (NVAX)

Tesla Motors Inc (NASDAQ:TSLA) jumped 2.57% in pre-market trading after the electric auto-maker received an Outperform rating and by Oppenheimer analyst Colin Rusch this morning. Rusch provided a $340 price target, marking a 38% potential upside from current levels. The analyst noted, “We continue to believe that a successful launch and ramp of the Model X are largely priced into TSLA shares but that a ramp of the gigafactory, proving the market for stationary storage, and the Model 3 are still not reflected in the current price.” He notes several near-term catalysts such the launch of stationary storage products in the fourth quarter, and also points to the timely ramp of the Gigafactory. Tesla unveiled its Model X yesterday, expanding the company’s product offerings with the compact SUV. According to the 18 analysts polled by TipRanks in the last 3 months, 11 are bullish on Tesla, 4 are bearish, and 3 are neutral. The average 12-month price target between the 18 analysts is $312.14, marking a 26% potential upside from current levels.

Click here to view Colin Rusch’s rating history and performance.

OvaScience Inc (NASDAQ:OVAS) rebounded 2.92% in pre-market trading this morning up to $8.82 after the stock plummeted 40% yesterday after the company withdrew its guidance for its 2015 AUGMENT cycle. AUGMENT, the company’s lead treatment, aims to improve the egg health when a woman goes through in vitro fertilization. Despite the revision, Rohit Vanjani of Oppenheimer maintained an Outperform rating on the stock but slashed his price target from $60 to $12. Vanjani explains, “We still believe in the technology behind the procedure. The story now revolves around forecasting a more conservative ramp.” The analyst changed his AUGMENT cycles estimate from 1,000 cycles in 2016 to about 2,700 cycles in 2017. According to the two analysts polled by TipRanks in the last 3 months, both of them are bullish on the company. However the new average 12-month price target is $29, marking a 238% potential upside from current levels.

Click here to view Rohit Vanjani’s rating history and performance.

Petroleo Brasileiro SA – Petrobras (ADR) (NYSE:PBR) increased 7.97% to $4.20 after the Brazilian oil company raised its fuel prices for the first time in one year. Investors hope that this price increase will mitigate the impact of falling oil prices and Brazil’s weakening currency. The oil company announced this morning a 6% readjustment to the price of gasoline and a 4% readjustment to the price of diesel. The price changes will be implemented immediately. This move comes as oil prices have been grappling to stay afloat for over a year due to falling on a global scale. Shares of PBR have plummeted 70% in the last 12 months. According to the 5 analysts polled by TipRanks in the last 3 months, only one analyst is bullish on the oil company while three are bearish and one is staying on the sidelines. The average 12-month price target between the five analysts is $7.40, marking a 90% potential upside from current levels.

Novavax, Inc. (NASDAQ:NVAX) spiked 7.64% in pre-market trading up to $6.90 after Bill Cramer met with CEO Stanley Erck in light of the company’s recent announcement of positive data on its RSV vaccine trial. The data centered on the vaccine’s application in pregnant woman and then followed the newborns for six months. Erck was pleased with the results but remains focused on trials for pipeline vaccines aimed at treating other viruses. Cramer assured that the recent decline in the company’s share price is unrelated to its accomplishments as he touted Novavax’s progress. In the past month, NVAX share prices have fallen about 40%. Like Cramer, Piper Jaffray analyst Edward Tenthoff is also bullish on the stock as he commented yesterday, attributing his bullishness to the recent selloff. According to TipRanks, both analysts who have rated the company in the last three months are bullish on the stock.

Click here to view Edward Tenthoff’s rating history and performance.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts